Moleculin Biotech Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Moleculin Biotech's estimated annual revenue is currently $5.4M per year.(i)
  • Moleculin Biotech's estimated revenue per employee is $201,000

Employee Data

  • Moleculin Biotech has 27 Employees.(i)
  • Moleculin Biotech grew their employee count by 29% last year.

Moleculin Biotech's People

NameTitleEmail/Phone
1
CMO - Part-timeReveal Email/Phone
2
VP, Drug Development Portfolio ManagementReveal Email/Phone
3
VP, Clinical OperationsReveal Email/Phone
4
Associate Director Clinical OperationsReveal Email/Phone
5
Associate Director OperationsReveal Email/Phone
6
Chief Financial Officer and EVPReveal Email/Phone
7
Chief Medical Officer – New ProductsReveal Email/Phone
8
Chief Science OfficerReveal Email/Phone
9
Senior Program ManagerReveal Email/Phone
10
Assistant ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.7M13320%N/AN/A
#2
$13.5M676%N/AN/A
#3
$16.1M80-2%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$10.1M506%N/AN/A
#6
$119.4M59427%N/AN/A
#7
$22.9M1148%N/AN/A
#8
$92.9M4628%N/AN/A
#9
$11.3M56-8%N/AN/A
#10
$7M356%N/AN/A
Add Company

What Is Moleculin Biotech?

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical-stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer, and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$5.4M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Moleculin Biotech News

2022-04-19 - Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly...

2022-04-17 - Should You Sell Moleculin Biotech Inc (MBRX) Stock Friday Morning?

In the Biotechnology industry, which ranks 136 out of 146 industries, Moleculin Biotech Inc ranks higher than 12% of stocks.

2022-04-06 - /C O R R E C T I O N -- Moleculin Biotech, Inc./

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.1M27-37%$289.6M
#2
$3.4M270%N/A
#3
$2.7M27N/AN/A
#4
$2.7M27N/AN/A
#5
$2.7M27N/AN/A